Fish Oil Protects the Blood-brain Barrier Integrity in a Mouse Model of Alzheimer's Disease

Overview

Journal Chin Med

Publisher Biomed Central

Specialty Biomedical Engineering

Date 2020 Apr 8

PMID 32256685

Citations 6

Authors

Youna Xie

Lingli Yan

Haitao Zeng

Weineng Chen

Jia-Hong Lu

Jian-Bo Wan

Huanxing Su

Xiaoli Yao

Affiliations

Soon will be listed here.

Abstract

Background: Alzheimer's disease (AD) is ranked as the most prevalent neurodegenerative disease. However, the exact molecular mechanisms underlying pathophysiological alterations in AD remain unclear, especially at the prodromal stage. The decreased proteolytic degradation of Aβ, blood-brain barrier (BBB) disruption, and neuroinflammation are considered to play key roles in the course of AD.

Methods: Male APPswe/PS1dE9 C57BL/6 J double-transgenic (APP/PS1) mice in the age range from 1 month to 6 months and age-matched wild type mice were used in this study, intending to investigate the expression profiles of Aβ-degrading enzymes for Aβ degradation activities and zonula occludens-1 (zo-1) for BBB integrity at the prodromal stage.

Results: Our results showed that there were no significant genotype-related alterations in mRNA expression levels of 4 well-characterized Aβ-degrading enzymes in APP/PS1 mice within the ages of 6 months. Interestingly, a significant decrease in zo-1 expression was observed in APP/PS1 mice starting from the age of 5 months, suggesting that BBB disrupt occurs at an early stage. Moreover, treatment of fish oil (FO) for 4 weeks remarkably increased zo-1 expression and significantly inhibited the glial activation and NF-κB activation in APP/PS1 mice.

Conclusion: The results of our study suggest that FO supplement could be a potential therapeutic early intervention for AD through protecting the BBB integrity and suppressing glial and NF-κB activation.

Citing Articles

The protective efficacy of omega-3 polyunsaturated fatty acids on oxidative stress, inflammation, neurotransmitter perturbations, and apoptosis induced by monosodium glutamate in the brain of male rats.

Essawy A, Jimmiey E, Abdel-Wahab W, Ali R, Eweda S, Abdou H Metab Brain Dis. 2025; 40(1):114.

PMID: 39878784 PMC: 11779784. DOI: 10.1007/s11011-025-01539-4.

Blood-spinal cord barrier disruption in degenerative cervical myelopathy.

Kim H, Yong H, Shea G Fluids Barriers CNS. 2023; 20(1):68.

PMID: 37743487 PMC: 10519090. DOI: 10.1186/s12987-023-00463-y.

ω-3 Polyunsaturated Fatty Acids Improve the Blood-Brain-Barrier Integrity in Contrast-Induced Blood-Brain-Barrier Injury in Uremic Mice.

Shin J, Park H, Choi H, Chang Y, Kim J, Ham Y Int J Mol Sci. 2023; 24(15).

PMID: 37569545 PMC: 10418677. DOI: 10.3390/ijms241512168.

Supplementation with dietary omega-3 PUFA mitigates fetal brain inflammation and mitochondrial damage caused by high doses of sodium nitrite in maternal rats.

Sun J, Zhang W PLoS One. 2022; 17(3):e0266084.

PMID: 35324981 PMC: 8947126. DOI: 10.1371/journal.pone.0266084.

Blood-Brain Barrier Disruption Mediated by FFA1 Receptor-Evidence Using Miniscope.

Lindenau K, Barr J, Higgins C, Sporici K, Brailoiu E, Brailoiu G Int J Mol Sci. 2022; 23(4).

PMID: 35216375 PMC: 8875452. DOI: 10.3390/ijms23042258.

References

Wolburg H, Lippoldt A . Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol. 2003; 38(6):323-37. DOI: 10.1016/s1537-1891(02)00200-8. View

Kanemitsu H, Tomiyama T, Mori H . Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci Lett. 2003; 350(2):113-6. DOI: 10.1016/s0304-3940(03)00898-x. View

Green K, Martinez-Coria H, Khashwji H, Hall E, Yurko-Mauro K, Ellis L . Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci. 2007; 27(16):4385-95. PMC: 6672302. DOI: 10.1523/JNEUROSCI.0055-07.2007. View

Ujiie M, Dickstein D, Carlow D, Jefferies W . Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation. 2004; 10(6):463-70. DOI: 10.1038/sj.mn.7800212. View

Erickson M, Banks W . Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. J Cereb Blood Flow Metab. 2013; 33(10):1500-13. PMC: 3790938. DOI: 10.1038/jcbfm.2013.135. View

Atri A, Frolich L, Ballard C, Tariot P, Molinuevo J, Boneva N . Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials. JAMA. 2018; 319(2):130-142. PMC: 5833662. DOI: 10.1001/jama.2017.20373. View

Fanning A, Ma T, Anderson J . Isolation and functional characterization of the actin binding region in the tight junction protein ZO-1. FASEB J. 2002; 16(13):1835-7. DOI: 10.1096/fj.02-0121fje. View

Liu Q, Wu D, Ni N, Ren H, Luo C, He C . Omega-3 polyunsaturated fatty acids protect neural progenitor cells against oxidative injury. Mar Drugs. 2014; 12(5):2341-56. PMC: 4052293. DOI: 10.3390/md12052341. View

Egan M, Kost J, Tariot P, Aisen P, Cummings J, Vellas B . Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. N Engl J Med. 2018; 378(18):1691-1703. PMC: 6776074. DOI: 10.1056/NEJMoa1706441. View

10.

Wang D, Dickson D, Malter J . beta-Amyloid degradation and Alzheimer's disease. J Biomed Biotechnol. 2006; 2006(3):58406. PMC: 1559921. DOI: 10.1155/JBB/2006/58406. View

11.

Shi Z, Ren H, Luo C, Yao X, Li P, He C . Enriched Endogenous Omega-3 Polyunsaturated Fatty Acids Protect Cortical Neurons from Experimental Ischemic Injury. Mol Neurobiol. 2015; 53(9):6482-6488. DOI: 10.1007/s12035-015-9554-y. View

12.

Funato H, Yoshimura M, KUSUI K, Tamaoka A, Ishikawa K, Ohkoshi N . Quantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer's disease. Am J Pathol. 1998; 152(6):1633-40. PMC: 1858449. View

13.

Mendes P, Park M, Maciel A, E Silva D, Friedrich N, Barbosa E . Kinetics of arterial carbon dioxide during veno-venous extracorporeal membrane oxygenation support in an apnoeic porcine model. Intensive Care Med Exp. 2016; 4(1):1. PMC: 4703593. DOI: 10.1186/s40635-015-0074-x. View

14.

Wan W, Cao L, Liu L, Zhang C, Kalionis B, Tai X . Aβ(1-42) oligomer-induced leakage in an in vitro blood-brain barrier model is associated with up-regulation of RAGE and metalloproteinases, and down-regulation of tight junction scaffold proteins. J Neurochem. 2015; 134(2):382-93. DOI: 10.1111/jnc.13122. View

15.

Van Itallie C, Fanning A, Bridges A, Anderson J . ZO-1 stabilizes the tight junction solute barrier through coupling to the perijunctional cytoskeleton. Mol Biol Cell. 2009; 20(17):3930-40. PMC: 2735491. DOI: 10.1091/mbc.e09-04-0320. View

16.

Mueller-Steiner S, Zhou Y, Arai H, Roberson E, Sun B, Chen J . Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron. 2006; 51(6):703-14. DOI: 10.1016/j.neuron.2006.07.027. View

17.

Fanning A, Jameson B, Jesaitis L, Anderson J . The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J Biol Chem. 1998; 273(45):29745-53. DOI: 10.1074/jbc.273.45.29745. View

18.

Higuchi M, Iwata N, Saido T . Understanding molecular mechanisms of proteolysis in Alzheimer's disease: progress toward therapeutic interventions. Biochim Biophys Acta. 2005; 1751(1):60-7. DOI: 10.1016/j.bbapap.2005.02.013. View

19.

Hardy J, Selkoe D . The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297(5580):353-6. DOI: 10.1126/science.1072994. View

20.

. Age-dependent white matter inflammation and cognitive impairment in the TgAPP21 rat model of Alzheimer disease. Neurology. 2018; 91(5):242. DOI: 10.1212/WNL.0000000000005930. View